ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

STX Shield Therapeutics Plc

1.925
0.00 (0.00%)
22 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Shield Therapeutics Plc LSE:STX London Ordinary Share GB00BYV81293 ORD 1.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.925 1.85 2.00 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 4.47M -40.44M -0.0522 -0.37 14.89M
Shield Therapeutics Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker STX. The last closing price for Shield Therapeutics was 1.93p. Over the last year, Shield Therapeutics shares have traded in a share price range of 1.075p to 12.75p.

Shield Therapeutics currently has 775,429,360 shares in issue. The market capitalisation of Shield Therapeutics is £14.89 million. Shield Therapeutics has a price to earnings ratio (PE ratio) of -0.37.

Shield Therapeutics Share Discussion Threads

Showing 7326 to 7347 of 23300 messages
Chat Pages: Latest  296  295  294  293  292  291  290  289  288  287  286  285  Older
DateSubjectAuthorDiscuss
16/12/2020
18:21
Well i commented on Tim several months ago he is a finance guy not a CEO.
I have 3 major issues with what I listened too 1st the reasons given for the late failure of the two companies made no sense and is clearly in my opinion not believable
2nd You would have thought the need for more urgency as to the chosen path after 18 months and yet we have to wait another 3 months 3 rd he was asked the question twice and I have mentioned on this thread the lack of apparent communication with Nordgine on the current sales progress and he refused to comment.
While the product clearly as great potential I feel we will endure further weakness as the 50% fundraise will be sub 50p and the big holders will already know the price so will continue to off load

best1467
16/12/2020
18:12
I understand his point that there is also risk associated with a poor performing licensee. The point is rammed home by the fact that he can't answer questions relating to Norgine in Europe. If they build the right team in the US and don't try to skimp on the finances then they control the risk and have every chance of success. They screwed up in Europe because they ran out of money. Don't make the same mistake again Tim!
whatno
16/12/2020
18:04
Some "have a go" smaller companies want to sell it but obviously a no go for Shield to the extent of Shield going it alone rather than going down that route.

Key take away: 'Minimal interest from “Big Pharma” companies'

parc1
16/12/2020
18:00
Waggle i thought the same thing!
powerp2
16/12/2020
17:57
I know it is hard at times but people need to do their best to get past his presentation capabilities or lack thereof... and try to see the detail in the presentation. That element is not going to change.

According to company announcements he signed a one year contract when Carl left and he's clearly said they have US-based people lined up if they do it themselves, so he is a caretaker. He is NOT going to lead the US push

More importantly for me the company needs to decide what is it to be as even during the presentation it wasn't clear what their preference is... SO please decide to commercialise or licence and commit to it without yet more delay and follow that through to fruition (or failure) AND critically make the decision clear in positive proactive communications to shareholders and the wider market as the last week's debacle is simply not acceptable.

ekcs
16/12/2020
17:50
I've put a few questions out and he's ignored some
Strong feeling that people don't believe him anymore

powerp2
16/12/2020
17:49
Yes I noticed the side step. He didnt address my q about the inexperience of the BoD
t0pgrader
16/12/2020
17:46
He is not qualified to lead the US team of consultants. I like the story but not the CEO.
t0pgrader
16/12/2020
17:44
he is an appalling presenter and does not seem to realise that his sitting on the fence until at least the end of the first quarter iro license or direct is the worst of both worlds?
waggle
16/12/2020
17:42
Just implausible that the company proceeds alone in USA with this CEO
t0pgrader
16/12/2020
17:20
A decent summary of the detail in the planning slide plus the revenue expectations slide are the things that should have been in the RNS. WOuld have given far far more colour and it propbably would not have been taken so flipping negatively.

What an own goal communication that was. I hope they learn their lesson.

ekcs
16/12/2020
17:20
Appalling presenter - basically reading the slides. If one of my first year undergraduates did this, I would fail them. Unimpressive
toffeeman
16/12/2020
16:48
Thanks - Sound working - problem my end!
rickus
16/12/2020
16:45
We all know the drug works. We want to know why 3rd parties aren't convinced such that you've not got a deal done 14 months after FDA approval!
ekcs
16/12/2020
16:43
Why bother with all this preamble. He must know we are not interested in background...
Get to the meat of the matter Tim

ekcs
16/12/2020
16:40
Yes got sound try refreshing the link
dubai123
16/12/2020
16:36
Got it on mobile, not on laptop
rickus
16/12/2020
16:36
Anyone getting the sound on the presentation?
rickus
16/12/2020
13:58
Questions were closed as of 9.30am yesterday morning but an Investormeet guy kindly agreed to accept mine and pass them on to management late in the day.

I've asked not for anything new just clarity on what they've already said, like actual reason for talks faltering (not the product), when did it become clear a separate strategy was needed, where are the current potential funders (prelim talks) from US or UK, equity element, approx timeframe for getting DIY up and running, etc., nothing they would be prohibited from answering. But if they blank or fudge them that will be their answer.

paleje
16/12/2020
09:50
My experience of AIM is that when a significant percentage of shares are held by PI's you can expect some sort of chicanory that will induce the "market" to suffer a calamatous fall. All to the benefit of company insiders and the NOMAD/MM's of course. Tim's timing of his " skin in the game" shares purchase speaks for itself
kop202
16/12/2020
07:08
Unfortunately it’s already been stated that no material different news will be available. And all PI questions are pre submitted I my opinion it will be uncomfortable but a pointless exercise as far as the answers we would all like
best1467
15/12/2020
23:47
Ask the the questions tomorrow, all the awkward ones, if he doesnt answer or lies hiding behind 'confidentiality' etc then we know we've got a problem. But let's see.

There's still time to ask, the more the better imo.

paleje
Chat Pages: Latest  296  295  294  293  292  291  290  289  288  287  286  285  Older